Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced second-quarter 2026 net product revenue of approximately $13.5 million, a significant increase from $2 million in the same period last year. The growth was primarily driven by about $11 million in net sales of TONMYA, its recently approved treatment for fibromyalgia. The company reported 12,592 total prescriptions for TONMYA during the quarter, a 100% sequential increase, with new patient prescriptions up 36% and refills surging 207%. This impressive performance underscores the market's acceptance of the first new fibromyalgia treatment in over 15 years.
TONMYA's market access has expanded rapidly, with coverage now representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to grow to about 145 million lives once a managed Medicare agreement takes effect on January 1, 2027. Such widespread coverage is critical for patient access and is likely to sustain the upward sales trajectory.
Beyond TONMYA's commercial success, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study evaluating TNX-102 SL for major depressive disorder (MDD). This study could open new indications for the drug, expanding its therapeutic potential. Additionally, Tonix is preparing to initiate an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. This candidate, a monoclonal antibody, represents a novel approach to prophylaxis against Lyme disease, addressing a significant unmet medical need.
The company's financial position remains solid, ending the quarter with approximately $176.2 million in cash and cash equivalents. According to management, these resources, along with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This runway provides the company with the flexibility to execute its strategic plans and continue investing in its pipeline.
The strong quarterly results and pipeline progress highlight Tonix's transformation into a fully integrated, commercial-stage biotechnology company. With TONMYA gaining traction and multiple later-stage programs in development, the company is well-positioned to create long-term value for shareholders and address high unmet medical needs in CNS and immunology.
For more details on the financial results and pipeline updates, interested parties can view the full press release at https://nnw.fm/6Yytj. For the latest news and updates on Tonix Pharmaceuticals, visit the company's newsroom at https://nnw.fm/TNXP.
